IRIDEX (IRIX) Projected to Post Earnings on Thursday

IRIDEX (NASDAQ:IRIX) is expected to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $14.74 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 5:00 PM ET.

IRIDEX Stock Performance

IRIDEX stock opened at $1.33 on Thursday. The company has a debt-to-equity ratio of 62.29, a quick ratio of 1.35 and a current ratio of 1.94. The stock has a market cap of $22.86 million, a PE ratio of -4.43 and a beta of 0.67. The stock has a 50-day moving average of $1.40 and a two-hundred day moving average of $1.20. IRIDEX has a one year low of $0.78 and a one year high of $1.65.

Analyst Upgrades and Downgrades

IRIX has been the topic of several recent analyst reports. Alliance Global Partners assumed coverage on shares of IRIDEX in a report on Thursday, February 5th. They set a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of IRIDEX in a research report on Monday, December 29th. Finally, iA Financial set a $3.00 price target on shares of IRIDEX in a research note on Thursday, February 5th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Citadel Advisors LLC lifted its holdings in shares of IRIDEX by 62.7% during the third quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 42,202 shares during the period. Apexium Financial LP increased its holdings in IRIDEX by 53.0% in the 3rd quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 34,834 shares during the period. Susquehanna International Group LLP raised its position in IRIDEX by 46.2% during the 3rd quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after buying an additional 17,834 shares during the last quarter. Finally, Jane Street Group LLC raised its position in IRIDEX by 93.9% during the 4th quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 15,377 shares during the last quarter. 20.10% of the stock is owned by institutional investors and hedge funds.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.